Post Intravitreal Injection Topical NSAID vs. Patching

NCT03918590 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Neovascular Age-related Macular Degeneration
Diabetic Macular Edema
Retinal Vein Occlusion

Interventions

DRUG: nepafenac 0.3% suspension (Ilevro; Alcon, Fort Worth, TX)
DRUG: Theratears tear drop, (Akron, Ann 111 Arbor, MI)
OTHER: patching

Sponsor

The New York Eye & Ear Infirmary